Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy

Open access

Abstract

Whereas significant anti-tumor responses are observed in most BRAF V600E -mutant melanoma patients exposed to MAPK-targeting agents, resistance almost invariably develops. Here, we show that in therapy-responsive cells BRAF inhibition induces downregulation of the processing of Sterol Regulator Element Binding (SREBP-1) and thereby lipogenesis. Irrespective of the escape mechanism, therapy-resistant cells invariably restore this process to promote lipid saturation and protect melanoma from ROS-induced damage and lipid peroxidation. Importantly, pharmacological SREBP-1 inhibition sensitizes BRAF V600E -mutant therapy-resistant melanoma to BRAF V600E inhibitors both in vitro and in a pre-clinical PDX in vivo model. Together, these data indicate that targeting SREBP-1-induced lipogenesis may offer a new avenue to overcome acquisition of resistance to BRAF-targeted therapy. This work also provides evidence that targeting vulnerabilities downstream of oncogenic signaling offers new possibilities in overcoming resistance to targeted therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-018-04664-0

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 De novo lipogenesis is inhibited by vemurafenib in therapy-sensitive cells, but remains activated in therapy-resistant ones. a Significantly altered (fold change of at least 1.5 and p < 0.05) pathways as indicated by ingenuity pathway analysis (IPA) of RNA-seq of vemurafenib (5 μM) treated M249 and A375 cells (n = 3). b Vemurafenib affects major components of the fatty acid synthesis pathway (fatty acid synthase, ATP citrate lyase and acetyl-CoA carboxylase). c The effects of vemurafenib treatment on the mRNA levels of FASN, ACLY, and ACACA in therapy-sensitive versus resistant BRAF-mutant cell lines and in NHEM (n = 3). d Vemurafenib or vehicle treated cells were assayed for their ability to incorporate 14C-acetate into lipids. Data are represented as mean ± s.e.m. The significance was determined with an unpaired t-test and compares vemurafenib-treated cells to their matching controls (n = 3). (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). e Heatmap of log2 ratios of the abundance of phospholipid species in vemurafenib-treated cells over vehicle treated cells. Species are indicated by their total number of fatty acid carbons, followed by a colon and the total number of unsaturations (n = 3). f log2 ratios of the vemurafenib-induced changes in saturation index. The saturation index was calculated by summing the species with the same level of unsaturations
Fig. 1 De novo lipogenesis is inhibited by vemurafenib in therapy-sensitive cells, but remains activated in therapy-resistant ones. a Significantly altered (fold change of at least 1.5 and p < 0.05) pathways as indicated by ingenuity pathway analysis (IPA) of RNA-seq of vemurafenib (5 μM) treated M249 and A375 cells (n = 3). b Vemurafenib affects major components of the fatty acid synthesis pathway (fatty acid synthase, ATP citrate lyase and acetyl-CoA carboxylase). c The effects of vemurafenib treatment on the mRNA levels of FASN, ACLY, and ACACA in therapy-sensitive versus resistant BRAF-mutant cell lines and in NHEM (n = 3). d Vemurafenib or vehicle treated cells were assayed for their ability to incorporate 14C-acetate into lipids. Data are represented as mean ± s.e.m. The significance was determined with an unpaired t-test and compares vemurafenib-treated cells to their matching controls (n = 3). (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). e Heatmap of log2 ratios of the abundance of phospholipid species in vemurafenib-treated cells over vehicle treated cells. Species are indicated by their total number of fatty acid carbons, followed by a colon and the total number of unsaturations (n = 3). f log2 ratios of the vemurafenib-induced changes in saturation index. The saturation index was calculated by summing the species with the same level of unsaturationsCC BY · PubMed Central
Fig. 2 Effects of vemurafenib on lipid metabolism involves SREBP-1. a Diagram illustrating the processing of SREBP: through SCAP interaction, SREBP is transported from the ER to the Golgi where it is consecutively cleaved by two proteases, yielding transcriptionally active, mature SREBP (mSREBP). b–d Western analysis of SREBP-1 (full-length and mature) and pMEK (Ser217/221). GAPDH is used as a loading control. b Western blot analysis for mSREBP levels in response to vemurafenib treatment in sensitive and resistant cells. c Western blot analysis of BRAF wild-type (but NRAS mutant) melanoma cells M202 and M207 treated with vemurafenib (5 μM). d Western blot analysis of BRAF wild-type, NRAS mutant melanoma cells, 72 h after transfection with pBABE-Puro BRAFV600E. e Diagram illustrating the HA-SREBP-1(Y335R)-myc construct. The Y335R mutation renders the construct transcriptionally inactive. f Confocal analysis of 451lu cells expressing HA-SREBP-1(Y335R)-myc. A PDI antibody was used to mark the ER and GM130 was used for cis-Golgi. Scale bar indicates 25 μM
Fig. 2 Effects of vemurafenib on lipid metabolism involves SREBP-1. a Diagram illustrating the processing of SREBP: through SCAP interaction, SREBP is transported from the ER to the Golgi where it is consecutively cleaved by two proteases, yielding transcriptionally active, mature SREBP (mSREBP). b–d Western analysis of SREBP-1 (full-length and mature) and pMEK (Ser217/221). GAPDH is used as a loading control. b Western blot analysis for mSREBP levels in response to vemurafenib treatment in sensitive and resistant cells. c Western blot analysis of BRAF wild-type (but NRAS mutant) melanoma cells M202 and M207 treated with vemurafenib (5 μM). d Western blot analysis of BRAF wild-type, NRAS mutant melanoma cells, 72 h after transfection with pBABE-Puro BRAFV600E. e Diagram illustrating the HA-SREBP-1(Y335R)-myc construct. The Y335R mutation renders the construct transcriptionally inactive. f Confocal analysis of 451lu cells expressing HA-SREBP-1(Y335R)-myc. A PDI antibody was used to mark the ER and GM130 was used for cis-Golgi. Scale bar indicates 25 μMCC BY · PubMed Central
Fig. 3 SREBP-1 contributes to membrane saturation and therapy resistance. a Lipidomic (phosphatidylcholine) profiles of 451lu and 451lu R cells treated with vemurafenib (5 μM) and SREBP inhibitors fatostatin and betulin (n = 3). b Lipidomics of hetero- and homozygous CRISPR-Cas9 knockouts of SREBF-1 in combination with vemurafenib treatment (n = 3). c Proliferation curves of 451lu and 451lu R cells treated with vemurafenib and fatostatin or betulin (phase contrast density measured by the Incucyte system, raw images and bar graph are shown in Supplementary Figs. 10, 11) (n = 4). d 451lu and 451lu R cells were treated with SREBP inhibitors and vemurafenib and were assayed for their ability to form colonies in soft agar, raw images and bar graph are shown in Supplementary Fig. 12 (n = 3). e Proliferation curves of 451lu R SREBP KO cells, raw images and bar graph are shown in Supplementary Figs. 13, 14 (n = 4). f SREBF-1 KO 451lu R cells were assayed for their ability to form colonies in soft agar in presence or absence of vemurafenib, raw images and bar graph are shown in Supplementary Fig. 15 (n = 3). All data are represented as mean ± s.e.m. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001)
Fig. 3 SREBP-1 contributes to membrane saturation and therapy resistance. a Lipidomic (phosphatidylcholine) profiles of 451lu and 451lu R cells treated with vemurafenib (5 μM) and SREBP inhibitors fatostatin and betulin (n = 3). b Lipidomics of hetero- and homozygous CRISPR-Cas9 knockouts of SREBF-1 in combination with vemurafenib treatment (n = 3). c Proliferation curves of 451lu and 451lu R cells treated with vemurafenib and fatostatin or betulin (phase contrast density measured by the Incucyte system, raw images and bar graph are shown in Supplementary Figs. 10, 11) (n = 4). d 451lu and 451lu R cells were treated with SREBP inhibitors and vemurafenib and were assayed for their ability to form colonies in soft agar, raw images and bar graph are shown in Supplementary Fig. 12 (n = 3). e Proliferation curves of 451lu R SREBP KO cells, raw images and bar graph are shown in Supplementary Figs. 13, 14 (n = 4). f SREBF-1 KO 451lu R cells were assayed for their ability to form colonies in soft agar in presence or absence of vemurafenib, raw images and bar graph are shown in Supplementary Fig. 15 (n = 3). All data are represented as mean ± s.e.m. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001)CC BY · PubMed Central
Fig. 4 Re-sensitization to vemurafenib involves lipid peroxidation. a Oleate (20 μM) or a mixture of linoleate (10 μM) + linolenate (10 μM) was added to the culture medium of 451lu R SREBP+/− cells and 451lu R cells treated with either vemurafenib alone or a combination with fatostatin or betulin, raw images and bar graph are shown in Supplementary Figs. 23, 24 (n = 3). b Mitochondrial superoxide levels in 451lu R cells treated with vemurafenib and fatostatin; medium was supplemented with oleate or linoleate + linolenate (n = 3). c MDA levels normalized to protein content in 451lu R cells (n = 5). d Effect of alpha-tocopherol, ferrostatin and NAC supplementation on proliferation curves of 451lu R cells treated with vemurafenib + fatostatin, raw images and bar graph are shown in Supplementary Figs. 26, 27 (n = 4). e Proliferation curves of the therapy-sensitive cell lines M229 and 451lu treated with vemurafenib, alpha-tocopherol, ferrostatin, and NAC (phase contrast density measured by the Incucyte system) raw images and bar graph are shown in Supplementary Figs. 30, 31 (n = 3). All data are represented as mean ± s.e.m. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001)
Fig. 4 Re-sensitization to vemurafenib involves lipid peroxidation. a Oleate (20 μM) or a mixture of linoleate (10 μM) + linolenate (10 μM) was added to the culture medium of 451lu R SREBP+/− cells and 451lu R cells treated with either vemurafenib alone or a combination with fatostatin or betulin, raw images and bar graph are shown in Supplementary Figs. 23, 24 (n = 3). b Mitochondrial superoxide levels in 451lu R cells treated with vemurafenib and fatostatin; medium was supplemented with oleate or linoleate + linolenate (n = 3). c MDA levels normalized to protein content in 451lu R cells (n = 5). d Effect of alpha-tocopherol, ferrostatin and NAC supplementation on proliferation curves of 451lu R cells treated with vemurafenib + fatostatin, raw images and bar graph are shown in Supplementary Figs. 26, 27 (n = 4). e Proliferation curves of the therapy-sensitive cell lines M229 and 451lu treated with vemurafenib, alpha-tocopherol, ferrostatin, and NAC (phase contrast density measured by the Incucyte system) raw images and bar graph are shown in Supplementary Figs. 30, 31 (n = 3). All data are represented as mean ± s.e.m. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001)CC BY · PubMed Central
Fig. 5 SREBP-1 protects vemurafenib-resistant cells from lipid peroxidation. BRAFV600E-mutant PDX tumors (mel6 model) were transplanted into nude mice (NMRI-Fox1nu) which were blindly administered vehicle (n = 8), fatostatin (20 mg/kg) (n = 10), vemurafenib (20 mg/kg) (n = 10) or a combination of vemurafenib and fatostatin (n = 10) (daily by oral gavage). a Tumor size was measured blindly with digital calipers every 3 days. The tumor pictures in (b) show the tumors that represent the median of their respective cohort. c Expression of Ki67 protein in PDX tumors that represent the median of their respective cohort. Scale bars indicate 100 μm. d Lipidomics of PDX tumor homogenate. e MDA quantification of PDX tumor homogenate. The data represent the average over all mice for each cohort compared to the control. Data are represented as mean ± s.e.m. (**p < 0.01)
Fig. 5 SREBP-1 protects vemurafenib-resistant cells from lipid peroxidation. BRAFV600E-mutant PDX tumors (mel6 model) were transplanted into nude mice (NMRI-Fox1nu) which were blindly administered vehicle (n = 8), fatostatin (20 mg/kg) (n = 10), vemurafenib (20 mg/kg) (n = 10) or a combination of vemurafenib and fatostatin (n = 10) (daily by oral gavage). a Tumor size was measured blindly with digital calipers every 3 days. The tumor pictures in (b) show the tumors that represent the median of their respective cohort. c Expression of Ki67 protein in PDX tumors that represent the median of their respective cohort. Scale bars indicate 100 μm. d Lipidomics of PDX tumor homogenate. e MDA quantification of PDX tumor homogenate. The data represent the average over all mice for each cohort compared to the control. Data are represented as mean ± s.e.m. (**p < 0.01)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Cited by

See all 161

Metadata

Authors
Talebi, A., Dehairs, J., Rambow, F., Rogiers, A., Nittner, D., Derua, R., Vanderhoydonc, F., Duarte, J. A. G., Bosisio, F., Van den Eynde, K., Nys, K., Pérez, M. V., Agostinis, P., Waelkens, E., Van den Oord, J., Fendt, S.-M., Marine, J.-C., & Swinnen, J. V.
Affiliations
  • KU Leuven (BE)
  • VIB-KU Leuven Center for Cancer Biology (BE)
  • Universitair Ziekenhuis Leuven (BE)
Corresponding author
Swinnen, Johannes V.
Venue
Nature Communications
Published
2018-06-27
Volume
9
Issue
1
Pages
2500-2500
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2808863372
Cited by
155
References
67
Citations by year
2026: 13 · 2025: 21 · 2024: 22 · 2023: 21 · 2022: 24 · 2021: 13 · 2020: 20 · 2019: 20 · 2018: 1
FWCI
4.80
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lirias (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • KU Leuven (C16/15/073)
  • Fonds Wetenschappelijk Onderzoek (G0E0817N)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
SREBP1, lipogenesis, BRAF V600E mutation, melanoma, BRAF inhibitor resistance, MAPK signaling, lipid saturation, lipid peroxidation, reactive oxygen species, targeted therapy resistance, drug repurposing
MeSH terms
Vemurafenib, Animals, Antineoplastic Agents, Female, Humans, Male, Melanocytes, Melanoma, Mice, Nude, Mutation, Pyridines, Thiazoles, Signal Transduction, Down-Regulation, Gene Expression Regulation, Neoplastic, Mice, SCID, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Lipogenesis, Mice, Sterol Regulatory Element Binding Protein 1, Gene Knockout Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy. https://app.cochat.ai/papers/10.1038/s41467-018-04664-0
The paper
Talebi, A., Dehairs, J., Rambow, F., Rogiers, A., Nittner, D., Derua, R., Vanderhoydonc, F., Duarte, J. A. G., Bosisio, F., Van den Eynde, K., Nys, K., Pérez, M. V., Agostinis, P., Waelkens, E., Van den Oord, J., Fendt, S.-M., Marine, J.-C., & Swinnen, J. V. (2018). Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy. Nature Communications. https://doi.org/10.1038/s41467-018-04664-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.